PharmaEssentia Japan K.K.
Quick facts
Phase 3 pipeline
- P1101 · Hematology
P1101 is a recombinant human thrombopoietin (TPO) analog that stimulates platelet production by binding to the thrombopoietin receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about PharmaEssentia Japan K.K.
What is PharmaEssentia Japan K.K.'s pipeline?
PharmaEssentia Japan K.K. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include P1101.
Related
- Sector hub: All tracked pharma companies